This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Respected Neuropathologist Appointed New Editor-in-Chief Of The American Journal Of Pathology

PHILADELPHIA, January 3, 2013 /PRNewswire/ --

The editorial leadership of The American Journal of Pathology ( AJP) passed to the direction of esteemed neuropathologist Kevin A. Roth, M.D., Ph.D. on January 1, 2013.

Dr. Roth holds the Robert and Ruth Anderson Endowed Chair in Pathology at the University of Alabama at Birmingham (UAB).  Involved in experimental pathology research for nearly 30 years, he published his first paper in AJP while an M.D., Ph.D. student at Stanford University. Dr. Roth also possesses extensive editorial experience, having served as an Associate Editor for AJP since 2003 and as Editor-in-Chief of the Journal of Histochemistry and Cytochemistry from 2006 to 2010.

The AJP is the leading global forum for reporting quality original research on cellular and molecular mechanisms of disease. With over 100 years of history, the Journal is widely read by the pathology community and garners over 30,000 citations to its articles each year (Source: 2011 Journal Citation Reports).  Notably, Dr. Roth is also currently serving as Special Editor of the AJP Centennial Project, a special review series to celebrate the centennial of the American Society for Investigative Pathology (ASIP), which owns AJP.

Dr. Roth has served as a Councilor for ASIP from 2010 to 2012, and is currently the ASIP Vice President. His term as ASIP President begins in 2014. Regarding his editorial appointment, Dr. Roth stated, "It is a special honor to be named the new Editor-in-Chief of The American Journal of Pathology in this centenary year. AJP, the official journal of this esteemed society [ASIP], has historically been one of the most prestigious and frequently cited journals in the field of pathology, and it is my intent to enhance further the quality and recognition of the Journal."

Dr. Roth completed his postdoctoral training at Washington University, where he rose to professor in the Division of Neuropathology, Department of Pathology and Immunology, and in the Department of Molecular Biology and Pharmacology. Dr. Roth moved to UAB in 2002 and served as Director of the Division of Neuropathology until his appointment as Chair of Pathology in 2008.

Dr. Roth, a renowned researcher on the molecular regulation of neuronal cell death, was the founding director of the UAB Comprehensive Neuroscience Center, an interdisciplinary collaboration for neuroscience research, clinical care, and education. The long-term goals of Dr. Roth's own research are to understand the role of cell death in normal nervous system development and its significance in neuropathological conditions including nervous system neoplasia.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs